CYTK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CYTK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.
Cytokinetics's Days Sales Outstanding for the
three
months ended in Dec. 2023 was 103.2.
Cytokinetics's Days Inventory for the
three
months ended in Dec. 2023 was 0.
Cytokinetics's Days Payable for the
three
months ended in Dec. 2023 was 18.95.
Therefore, Cytokinetics's Cash Conversion Cycle (CCC) for the
three
months ended in Dec. 2023 was 84.25.
The historical data trend for Cytokinetics's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cytokinetics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Cash Conversion Cycle | Get a 7-Day Free Trial | 24.95 | 0.82 | 112.48 | 64.87 | 8.61 |
Cytokinetics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cash Conversion Cycle | Get a 7-Day Free Trial | 32.56 | -13.28 | 88.36 | 405.95 | 84.25 |
For the Biotechnology subindustry, Cytokinetics's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Cytokinetics's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Cytokinetics's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Cytokinetics's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as
Cash Conversion Cycle | = | Days Sales Outstanding | + | Days Inventory | - | Days Payable |
= | 34.66 | + | 0 | - | 26.05 | |
= | 8.61 |
Cytokinetics's Cash Conversion Cycle for the quarter that ended in Dec. 2023 is calculated as:
Cash Conversion Cycle | = | Days Sales Outstanding | + | Days Inventory | - | Days Payable |
= | 103.2 | + | 0 | - | 18.95 | |
= | 84.25 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cytokinetics (NAS:CYTK) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Thank you for viewing the detailed overview of Cytokinetics's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.
Robert I Blum | officer: EVP, Corp. Development & CBO | 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
John T Henderson | director | 320 WAKARA WAY, SALT LAKE CITY UT 84108 |
Fady Ibraham Malik | officer: SVP Research & Early Dev | 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Wendall Wierenga | director | 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130 |
Muna Bhanji | director | C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Robert Wong | officer: VP, Chief Accounting Officer | 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Ching Jaw | officer: SVP Finance & CFO | 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Sandford D Smith | director | C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
B Lynne Parshall | director | 2855 GAZELLE COURT, CARLSBAD CA 92010 |
Santo J Costa | director | |
Kaye Edward M. Md | director | 3450 MONTE VILLA PARKWAY, BOTHELL WA 98011 |
Robert Arthur Harrington | director | C/O CYTOKINETICS, INCORPORATED, 350 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080 |
Mark A Schlossberg | officer: SVP - Legal & General Counsel | C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544 |
David Cragg | officer: V.P., Human Resources | 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
L Patrick Gage | director | C/O NEOSE TECHNOLOGIES, 102 WITMER RD, HORSHAM PA 19044 |
From GuruFocus
By Marketwired • 10-03-2023
By sperokesalga sperokesalga • 05-15-2023
By GuruFocus Research • 12-29-2023
By Marketwired • 10-02-2023
By Marketwired • 07-27-2023
By Marketwired • 10-23-2023
By Marketwired • 07-05-2023
By Marketwired • 09-07-2023
By Marketwired • 08-03-2023
By sperokesalga sperokesalga • 06-02-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.